Objective: The pathological roles of Notch pathway in renal cell carcinoma are still unclear, although Notch signaling has been shown to have an effect on many malignant tumors. In this study, Jagged1 was detected to examine its expression pattern and clinical significance in renal cell carcinoma. Methods: Normal and cancerous kidney tissues from three renal cell carcinoma patients were analyzed using western blot and reverse transcriptase -polymerase chain reaction for Jagged1 expression. Subsequently, extensive immunohistochemistry was performed to detect Jagged1 expression in 129 renal cell carcinoma cases. Clinicopathological data for these patients were evaluated. The prognostic significance was assessed using the KaplanMeier survival estimates and log-rank tests. A multivariate study with the Cox proportional hazard model was used to evaluate the prognosis-related aspects. Results: Western blot and polymerase chain reaction results showed markedly increased Jagged1 protein and mRNA levels in renal cell carcinoma tissues compared with normal kidney tissues, which was further verified by immunohistochemical analysis. The expression level of Jagged1 was strongly associated with tumor size, nuclear grade and TNM stage. In addition, high Jagged1 expression was statistically linked to reduced overall and disease-free survival, especially at the early stage (P , 0.001 and ,0.001, respectively). Jagged1 expression was found to be an independent prognostic factor for both overall survival and disease-free survival in multivariate analysis (P ¼ 0.035 and 0.028, respectively). Conclusions: Notch signaling may play an important role in the progress of renal cell carcinoma. Jagged1 expression may be useful for predicting prognosis in patients with renal cell carcinoma, especially at the early stage.
INTRODUCTION
Each year, renal cell carcinoma (RCC) afflicts about 150 000 people globally and causes nearly 78 000 deaths (1) . Effective therapy for patients with metastatic advanced-stage RCC is still limited, although recent data show that treatment with multikinase inhibitors prolongs progression-free survival (2) .
Clear cell RCC, which accounts for 75% of all RCCs, is characterized by the inactivation of the von Hippel -Lindau (VHL) tumor suppressor gene (1) . Loss of VHL protein leads to oxygen-independent stabilization of HIF-1a subunits and up-regulates the expression of downstream targets including vascular endothelial growth factor (VEGF) which is involved in the regulation of cellular proliferation and angiogenesis (3) . However, with a better understanding in genetics and molecular biology, it had been postulated that additional signaling pathways were required for the genesis of clear cell RCC and may provide new therapeutic targets (4) .
The Notch pathway is highly conserved and plays a crucial role in multiple cellular processes including stem cell selfrenewal, cell fate determination, epithelial cell polarity/ adhesion, cell division and apoptosis in organisms throughout the animal kingdom (5) . Mammals have four Notch proteins (Notch1 -4) that function as receptors for five Notch ligands (Jagged1, 2 and Dll1, 3, 4) . Binding of ligands to receptors leads to proteolytic cleavage of the receptor and releases a cytoplasmic domain fragment from the plasma membrane. Notch intracellular domain can then enter the nucleus and activate the transcription of a group of downstream genes (6) .
Aberrant signaling within the Notch pathway is reported in multiple malignancies (7 -10) . Notch can either suppress or promote tumors, depending on signal strength, timing, cell type and contex (11) . Moreover, deregulated expression of Jagged1, a ligand of Notch pathway, was reported to be associated with prognosis (12, 13) . However, the pathological roles of Notch in RCC are still unclear. Therefore, in this study, we examined the expression and clinical significance of Jagged1 in RCC and explored the association between Jagged1 expression level and patient outcome.
PATIENTS AND METHODS

PATIENTS AND TISSUE SAMPLES
This study was approved by the ethical committee of Zhongshan Hospital, Fudan University (Approval no. 2008-98) and each patient participated after providing informed consent. For western blot and reverse transcriptasepolymerase chain reaction (RT -PCR), fresh tumor tissues (later verified as clear cell RCC) and normal (non-tumor) kidney tissues were obtained intra-operatively from three patients who underwent radical nephrectomy at the Department of Urology, Zhongshan Hospital. The tissue samples were then snap-frozen in liquid nitrogen and stored at -808C until analysis. For immunostaining of Jagged1, totally 129 patients with pathologically verified clear cell RCC were enrolled consecutively in this study. All patients had nephrectomy ( partial or radical) performed at the Department of Urology, Zhongshan Hospital, from 2003 to 2008. Staging procedures included physical examination, chest radiography, ultrasound or computerized tomography of the abdomen. Tumor stage was reclassified according to the TNM classification system 2002 (14) , and nuclear grading was performed according to Fuhrman et al.'s (15) system. All tissue samples were formalin-fixed and paraffin-embedded.
WESTERN BLOT
The three paired samples of RCC tissues and normal renal tissues were solubilized in a lysis buffer on ice. All lysates were centrifuged at 48C at 10 000 g for 10 min. The protein concentration was determined using the Bradford protein assay (Bio-Rad Laboratory, USA). An amount of 100 mg protein content from each sample was electrophoresed in 8% SDS -PAGE and blotted on a nitrocellulose membrane. The membrane was blocked with 5% bovine serum albumin in 1Â Tris-buffered saline (TBS) buffer at room temperature for 2 h and incubated with polyclonal goat anti-human Jagged1 antibody (1:500; sc-6011, Santa Cruz, CA, USA) at 48C overnight. After three washes for 15 min in TBS, the membrane was incubated with the peroxidase-conjugated mouse anti-goat IgG antibody for 2 h at room temperature. Immunoreactive proteins were visualized by an enhanced chemiluminescence system, and b-actin was used as the control for protein loading.
REVERSE TRANSCRIPTASE -POLYMERASE CHAIN REACTION
Total RNA was isolated from the three paired specimens of RCC tissues and normal renal tissues using the TRIzol reagent (Invitrogen) according to the manufacturer's instructions. cDNA was synthesized using First Strand cDNA Synthesis Kit (RevertAid) with oligo-dT as primers. After an initial denaturation step at 948C for 2 min, 25 cycles of amplification were performed at 948C for 30 s, 558C for 20 s and 728C for 45 s, followed by 10 min at 728C as an additional extension step in RT -PCR. PCR products were analyzed by electrophoresis on 1.5% agarose gels and visualized by ethidium bromide staining. GAPDH was used as a housekeeping gene. The primer sequences were: for Jagged1, 5
0 -TCGCTGTATCTGTCCACCTG-3 0 and 5 0 -AG TCACTGGCACGGTTGTAG-3 0 ; for GAPDH, 5 0 -GGAG TCCACTGGCGTCTTCACC-3 0 and 5 0 -GAGGAGTGGGT GTCGCTGTTG-3 0 .
IMMUNOHISTOCHEMISTRY
Immunohistochemistry was performed using standard techniques. Briefly, 4 mm paraffin-embedded tissue sections were dewaxed in xylene and rehydrated in graded alcohols. Endogenous peroxidase was blocked using 3% hydrogen peroxide. Antigen retrieval was accomplished by boiling tissue sections in 10 mM citrate buffer ( pH 6.0) for 10 min. Non-specific protein binding was performed by 30 min incubations with goat serum. These treatments were alternated with rinses in phosphate-buffered saline (PBS). The slides were then treated with polyclonal goat anti-human Jagged1 antibody (1:100; sc-6011, Santa Cruz) for 1 h at room temperature. Next, they were rinsed with PBS and incubated with the horseradish peroxidase-conjugated secondary antibody, followed by a rinse in PBS, incubation with 3,3 0 -diaminobenzidine staining and counterstaining with hematoxylin blue. Negative controls were performed by substituting the primary antibody with a non-immuned serum. Control sections were treated in parallel with the samples.
EVALUATION OF STAINING
All stained sections were evaluated by three independent investigators in a blind manner. The scoring was based on color intensity and extensity as reported previously (16) . Briefly, the proportion score was determined semiquantitatively by assessing the whole tumor section at low magnification, and each sample was scored on a scale of 0 -3, in which 0 ¼ no cells positive, 1 ¼ 1 -20% of cells positive, 2 ¼ 21 -60% and 3 ¼ 61 -100%. The intensity score was determined at high magnification as 0 ¼ negative staining, 1 ¼ weakly positive staining, 2 ¼ moderately positive staining and 3 ¼ strongly positive staining. Then, the total score of each section was calculated by the sum of two parameters. We then designated low expression as total score 0 -3, whereas high expression as total score 4 -6. Tumors were subdivided according to the protein expression level into different groups.
STATISTICAL ANALYSIS
The correlation of protein expression with clinical and pathological characteristics was tested by the x 2 test. The period of overall survival (OS) was measured from the date of surgery to the date of death or the last follow-up. Disease-free survival (DFS) was measured from the date of surgery to the date of disease relapse or death or the date of the last follow-up. OS and DFS curves were calculated using the Kaplan -Meier method and compared by the log-rank test. The Cox regression model was used for multivariate analysis. All the statistical analyses were performed using a statistical software package (SPSS, Version 15.0, Chicago, IL, USA). Statistical significance was defined as P , 0.05. All P-values were two-sided.
RESULTS
WESTERN BLOT AND RT -PCR
As Fig. 1 shows, the protein of Jagged1 was expressed in the adjacent non-neoplastic tissues and RCC tissues, with specific bands at 150 kDa. Jagged1 was found up-regulated in all cases of RCC tissues compared with non-neoplastic tissues. Similarly, Jagged1 mRNA was detected in all of the tumor samples. The expression of Jagged1 mRNA was higher in all tumor tissues than in non-neoplastic tissues. The results showed that the alteration in mRNA level for Jagged1 in RCC was consistent with the changes in the protein level.
CLINICAL AND PATHOLOGICAL CHARACTERISTICS
For immunostaining of Jagged1, totally 129 cases with clear cell RCC were enrolled in the study. The clinical and pathological characteristics of the patients are listed in Table 1 . The mean age of the patients at diagnosis was 55.5 years (range 27 -83 years), and the ratio of males to females was 2:1. Ninety-eight patients had Stage I/II disease (76%). Thirty-one patients had Stage III/IV disease (24%). One hundred and twenty-two patients had radical nephrectomy (94.6%) and the rest seven patients had nephron-sparing surgery (5.4%). The mean tumor size was 5.3 cm (range 1.5 -15.0 cm). The mean follow-up duration at the time of analysis was 47.2 months (range from 5 to 74 months). There were 86 patients alive without evidence of disease and 6 patients alive with disease. Of all the 37 deaths, 31 were cancer-related deaths and 6 were not related to the cancer.
IMMUNOHISTOCHEMISTRY
As shown in Fig. 2 , Jagged1 staining was present mainly in the cell membrane and/or cytoplasm. Nuclear staining was observed sparsely and no obvious significance was found in relation to the appearance and distribution of nuclear staining. The positive staining rate of Jagged1 in RCC tissues was 93.0% (120 of 129), compared with 42.4% (14 of 33) in normal kidney tissues. Jagged1 exhibited a significantly higher expression in RCC tissues than in normal kidney tissues (P , 0.05). We then designated low expression as total score 0 -3, whereas high expression as total score 4 -6. Tumors were subdivided according to the protein expression level into different groups. The expression level of Jagged1 was statistically correlated with nuclear grade (P ¼ 0.001), TNM stage (P ¼ 0.002) and tumor size (P ¼ 0.016). There was no correlation between Jagged1 expression and age or gender, as listed in Table 2 .
RELATIONSHIP OF JAGGED1 EXPRESSION AND PROGNOSIS
When analyzed in univariate analysis, high Jagged1 expression was statistically associated with reduced OS as well as DFS (P , 0.001 and ,0.001, respectively) as illustrated by the Kaplan -Meier curves (Fig. 3) . We next made the Kaplan -Meier curves of PFS and OS by the clinical To examine the independent prognostic significance of the expression of Jagged1, multivariate analysis was performed using the Cox regression model with clinical and pathological characteristics including age, gender, TNM stage, grade and tumor size. The expression of Jagged1 was an independent prognostic factor for both OS and DFS (P ¼ 0.035 and 0.028, respectively) ( Tables 3 and 4) .
DISCUSSION
The Notch pathway is critical in the determination of cell fates by regulating cell growth, differentiation and apoptosis. It plays either an oncogenic or a tumor suppressive role, depending on the cancer type, other signaling pathways involved and activation of Notch receptor. Deregulated expression of Notch receptors, ligands and targets is observed in many types of tumors (17, 18) . However, the expression pattern of Notch in RCC, as well as the relation with clinicopathological findings, remains poorly understood. In this study, the expression of Jagged1 was detected and it showed a membranous and/or cytoplasmic staining pattern by immunohistochemistry. The specificity of the antibody ( polyclonal goat anti-human Jagged1 antibody: sc-6011, Santa Cruz) used in immunoblotting was confirmed by western blot results. By immunohistochemistry, it was found that the level of expression of Jagged1 was significantly higher in RCC tissues than in non-neoplastic tissues, which was also confirmed by both western blot and RT-PCR analysis. Moreover, the expression level of Jagged1 was strongly correlated with tumor size, grade and TNM stage. Our study indicates that the Notch pathway might be related to tumorigenesis of RCC. One mechanism for the oncogenic role of Notch may derive from its ability to prevent differentiation and maintain unlimited proliferation (19) . Besides, several studies show that Notch signaling is pivotal for tumor angiogenesis (20 -22) : the expression of Dll4 was particularly high in RCC and was correlated with the expression of VEGF (23); Zeng et al. (24) demonstrated that in head and neck squamous cell carcinoma, cells overexpressing Jagged1 formed larger tumors with increased vascularization. In addition, there was a recent study showing that Notch1 and Jagged1 were expressed at significantly higher levels in RCC than in the normal human renal tissue, and the inhibition of Notch signaling was accompanied by elevated levels of the cyclindependent kinase inhibitors p21 and p27, suggesting that one mechanism by which Notch signaling promotes growth of RCC cells is by suppression of p21 and/or p27 (25) . Combined with our present results, we assume that Jagged1 might play an oncogenic role in RCC, although the functions and mechanism of Notch signaling in the development of RCC need further investigation.
Important prognostic factors for RCC include specific clinical signs or symptoms, tumor-related factors and various laboratory findings. In addition, a large variety of possible prognostic markers for RCC has been studied, e.g. HIF-1a, CAIX, VEGF etc. In this study, we investigated the role of Jagged1 in predicting the outcome of RCC patients. In univariate analysis, high expression of Jagged1 was statistically associated with decreased OS and DFS. However, when the Kaplan -Meier curves of PFS and OS was shown by the clinical stage, we found that high Jagged1 expression was statistically associated with reduced OS as well as DFS (both P , 0.001) in TNM I cases, yet not in other TNM stage groups. It may be because most cases (81 of 129, 62.8%) enrolled in our study were in TNM stage I. Thus, the sample sizes for cases with other stages may be inadequate to achieve statistically significant results of the Kaplan -Meier curves. In multivariate analysis, we analyzed TNM stage, grade, tumor size, age, gender as well as expression of Jagged1 using the Cox regression model. The results showed that the expression level of Jagged1 was an independent prognostic factor for OS and DFS. Consistent with this, a study demonstrated that high Jagged1 predicted poorer Jpn J Clin Oncol 2011;41(3) 415 outcome in breast cancer (12) . It is also reported that high Jagged1 expression was associated with prostate cancer recurrence (13) . It seems to us that a Jagged1-mediated Notch pathway activation loop was functioning to promote tumor formation and progression. However, some investigators have also given contradictory results. It was reported that the expression of Notch receptors was down-regulated and Notch signaling might function as a tumor suppressor in the progress of RCC (26) . Since Notch signaling is such a complicated and comprehensive pathway, the underlying detailed mechanism of this difference also requires further study including an extensive and complete study of all the receptors, ligands and even downstream target genes.
In summary, our study indicates that Notch signaling may play an important role in the progress of RCC. Jagged1 expression may be useful for predicting prognosis in patients with RCC, especially at the early stage. Our data also define a group of clear cell RCC that can be identified by screening for Jagged1 expression that may benefit from g-secretase inhibitor-based therapy (which would block Notch signaling).
